Back to results
US 7,247,718 B2Granted
Antibody recognizing a small subset of human hematopoietic cells
AssigneeMorphogenesis, Inc.
InventorsMichael J. P. Lawman, Patricia Lawman
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeMorphogenesis, Inc.
InventorsMichael J. P. Lawman, Patricia Lawman
Estimating the term…
The subject invention pertains to antibodies that have binding specificity for an antigen that is expressed on a subset of human, hematopoietic mononuclear cells, including a hematopoietic stem cell population, but is not expressed on normal, mature myeloid cells. In one embodiment, a monoclonal antibody, MG1, is provided. This antibody is useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marrow transplantation, genetic therapy, and in treating other diseases of the hematopoietic system. Cell suspensions containing MG1+ human hematopoietic cells are also provided, as well as therapeutic methods employing the cell suspensions. The subject invention also pertains to the novel antigen recognized by the subject antibodies.
An isolated polynucleotide molecule that encodes a polypeptide, or a fragment thereof, expressed on the surface of a subset of human CD34+ hematopoietic mononuclear cells, wherein said polypeptide irnmunoreacts with MG1 antibody, wherein said MG1 antibody is produced by the hybridoma cell line deposited under ATCC Accession No. HB12232, and wherein said polypeptide comprises the amino terminal amino acid sequence of SEQ ID NO:
An isolated polynucleotide molecule that encodes a polypeptide, or a fragment thereof, expressed on the surface of a subset of human CD34+ hematopoietic mononuclear cells, wherein said polypeptide immunoreacts with MG1 antibody, wherein said MG1 antibody is produced by the hybridoma cell line deposited under ATCC Accession No. HB12232, wherein said polypeptide comprises the amino terminal amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.